

Hemovigilance Module Adverse Reaction Transfusion Associated Graft vs. Host Disease

*Required for saving				
*Facility ID#: NHSN A	dverse Reaction #:			
Patient Information				
*Patient ID:				
Social Security #:	Secondary ID: Medicare #:			
Last Name:				
Ethnicity 🗌 Hispanic or Latino	Not Hispanic or Not Latino			
Race American Indian/Alaska Native Asian Black or African American				
□ Native Hawaiian/Other Pacific Islander □ White				
*Blood Group: 🗌 A- 🗌 A+ 🗌 I	B- □B+ □ AB- □ AB+ □ O- □ O+ □ Blood type not done			
	Rh + Transitional ABO / Rh - Transitional ABO / Transitional Rh D B/Transitional Rh Group O/Transitional Rh			
Patient Medical History				
List the patient's admitting diagno	sis. (Use ICD-10 Diagnostic codes/descriptions)			
Code:	Description:			
Code:	Description:			
Code:	Description:			
List the patient's underlying indica	ation for transfusion. (Use ICD-10 Diagnostic codes/descriptions)			
Code:	Description:			
Code:	Description:			
Code:	Description:			
List the patient's comorbid conditi reaction. (Use ICD-10 Diagnostic	ons at the time of the transfusion related to the adverseUNKNOWNcodes/descriptions)NONE			
Code:	Description:			
Code:	Description:			
Code:	Description:			
of any individual or institution is collected w stated, and will not otherwise be disclosed	ily provided information obtained in this surveillance system that would permit identification with a guarantee that it will be held in strict confidence, will be used only for the purposes or released without the consent of the individual, or the institution in accordance with Health Service Act (42 USC 242b, 242k, and 242m(d)).			
reviewing instructions, searching existing c collection of information. An agency may r unless it displays a currently valid OMB co	information is estimated to average 20 minutes per response, including the time for lata sources, gathering and maintaining the data needed, and completing and reviewing the not conduct or sponsor, and a person is not required to respond to a collection of information ntrol number. Send comments regarding this burden estimate or any other aspect of this ions for reducing this burden to CDC, Reports Clearance Officer, 1600 Clifton Rd., MS D-74, 6).			



•	nedical procedure including past procedures and procedures to be nt hospital or outpatient stay. (Use ICD-10 Procedure	UNKNOWN		
Code:	Description:			
Code:	Description:			
Code:	Description:			
Additional Information				
Transfusion History				
Has the patient received a	previous transfusion?	KNOWN		
] WB 🔲 RBC 🗌 Platelet 🗌 Plasma 🔲 Cryoprecipitate	Granulocyte		
Date of Transfusion:				
	e reaction transfusion-related?			
• •	n about the transfusion adverse reaction.			
Type of transfusion adverse reaction:				
	fy			
Reaction Details		•		
	// *Time reaction occurred:: Time u	nknown		
*Facility location where patie				
Is this reaction associated with an incident? Yes No If Yes, Incident #:				
Investigation Results				
	l graft vs. host disease (TA-GVHD)			
	l graft vs. host disease (TA-GVHD)			
* Transfusion associated *Case Definition	I graft vs. host disease (TA-GVHD) radiated blood product(s) in the two months preceding the reaction?	Yes No		
* Transfusion associated *Case Definition Did patient receive non-irr		Yes No		
* Transfusion associated *Case Definition Did patient receive non-irr	radiated blood product(s) in the two months preceding the reaction?	Yes No		
* Transfusion associated *Case Definition Did patient receive non-irr Check all that occurred w Clinical syndrome	radiated blood product(s) in the two months preceding the reaction?	_		
* Transfusion associated *Case Definition Did patient receive non-irr Check all that occurred w Clinical syndrome Clinical syndrome	radiated blood product(s) in the two months preceding the reaction?] Pancytopenia		
* Transfusion associated *Case Definition Did patient receive non-irr Check all that occurred w Clinical syndrome Clinical syndrome Liver dysfunct Characteristic	radiated blood product(s) in the two months preceding the reaction? within 2 days to 6 weeks after cessation of transfusion: e characteristics: Diarrhea Fever Hepatomegaly [tion (i.e., elevated ALT, AST, Alkaline phosphatase, and bilirubin) [c rash: erythematous, maculopapular eruption centrally that spreads	☐ Pancytopenia] Marrow aplasia to extremities and		
* Transfusion associated *Case Definition Did patient receive non-irr Check all that occurred w Clinical syndrome Clinical syndrome Liver dysfunct Characteristic	radiated blood product(s) in the two months preceding the reaction? within 2 days to 6 weeks after cessation of transfusion: e characteristics: Diarrhea Fever Hepatomegaly [tion (i.e., elevated ALT, AST, Alkaline phosphatase, and bilirubin)	☐ Pancytopenia] Marrow aplasia to extremities and		
* Transfusion associated *Case Definition Did patient receive non-irr Check all that occurred w Clinical syndrome Clinical syndrome Liver dysfunct Characteristic may, in severe ca	radiated blood product(s) in the two months preceding the reaction? within 2 days to 6 weeks after cessation of transfusion: e characteristics: Diarrhea Fever Hepatomegaly tion (i.e., elevated ALT, AST, Alkaline phosphatase, and bilirubin) c rash: erythematous, maculopapular eruption centrally that spreads ases, progress to generalized erythroderma and hemorrhagic bullous	☐ Pancytopenia] Marrow aplasia to extremities and		
* Transfusion associated *Case Definition Did patient receive non-irr Check all that occurred w Clinical syndrome Clinical syndrome Liver dysfunct Characteristic may, in severe ca Check all that apply: Characteristic histolo	radiated blood product(s) in the two months preceding the reaction? within 2 days to 6 weeks after cessation of transfusion: e characteristics: Diarrhea Fever Hepatomegaly [tion (i.e., elevated ALT, AST, Alkaline phosphatase, and bilirubin) [c rash: erythematous, maculopapular eruption centrally that spreads ases, progress to generalized erythroderma and hemorrhagic bullous ogical appearance of skin or liver biopsy.	☐ Pancytopenia] Marrow aplasia to extremities and		
* Transfusion associated *Case Definition Did patient receive non-irr Check all that occurred w Clinical syndrome Clinical syndrome Liver dysfunct Characteristic may, in severe ca	radiated blood product(s) in the two months preceding the reaction? within 2 days to 6 weeks after cessation of transfusion: e characteristics: Diarrhea Fever Hepatomegaly [tion (i.e., elevated ALT, AST, Alkaline phosphatase, and bilirubin) [c rash: erythematous, maculopapular eruption centrally that spreads ases, progress to generalized erythroderma and hemorrhagic bullous ogical appearance of skin or liver biopsy.	☐ Pancytopenia] Marrow aplasia to extremities and		
* Transfusion associated *Case Definition Did patient receive non-irr Check all that occurred w Clinical syndrome Clinical syndrome Liver dysfunct Characteristic may, in severe ca Check all that apply: Characteristic histolo	radiated blood product(s) in the two months preceding the reaction? within 2 days to 6 weeks after cessation of transfusion: e characteristics: Diarrhea Fever Hepatomegaly tion (i.e., elevated ALT, AST, Alkaline phosphatase, and bilirubin) c rash: erythematous, maculopapular eruption centrally that spreads ases, progress to generalized erythroderma and hemorrhagic bullous pogical appearance of skin or liver biopsy. not done.	☐ Pancytopenia] Marrow aplasia to extremities and		
 Transfusion associated *Case Definition Did patient receive non-irr Check all that occurred w Clinical syndrome Clinical syndrome Liver dysfunct Characteristic may, in severe case Check all that apply: Characteristic histole Biopsy negative or n 	radiated blood product(s) in the two months preceding the reaction? within 2 days to 6 weeks after cessation of transfusion: e characteristics: Diarrhea Fever Hepatomegaly tion (i.e., elevated ALT, AST, Alkaline phosphatase, and bilirubin) c rash: erythematous, maculopapular eruption centrally that spreads ases, progress to generalized erythroderma and hemorrhagic bullous pogical appearance of skin or liver biopsy. not done.	☐ Pancytopenia] Marrow aplasia to extremities and		
 Transfusion associated *Case Definition Did patient receive non-irr Check all that occurred w Clinical syndrome Clinical syndrome Liver dysfunct Characteristic may, in severe case Check all that apply: Characteristic histolo Biopsy negative or n Other signs and symptoms: 	radiated blood product(s) in the two months preceding the reaction? within 2 days to 6 weeks after cessation of transfusion: e characteristics: Diarrhea Pever Hepatomegaly tion (i.e., elevated ALT, AST, Alkaline phosphatase, and bilirubin) c rash: erythematous, maculopapular eruption centrally that spreads ases, progress to generalized erythroderma and hemorrhagic bullous ogical appearance of skin or liver biopsy. not done. : (check all that apply)	☐ Pancytopenia] Marrow aplasia to extremities and		
 Transfusion associated *Case Definition Did patient receive non-irr Check all that occurred w Clinical syndrome Clinical syndrome Liver dysfunct Characteristic may, in severe case Check all that apply: Characteristic histold Biopsy negative or n Other signs and symptoms: Generalized: 	radiated blood product(s) in the two months preceding the reaction? within 2 days to 6 weeks after cessation of transfusion: e characteristics: Diarrhea Fever Hepatomegaly [tion (i.e., elevated ALT, AST, Alkaline phosphatase, and bilirubin) [c rash: erythematous, maculopapular eruption centrally that spreads ases, progress to generalized erythroderma and hemorrhagic bullous ogical appearance of skin or liver biopsy. not done. : (check all that apply) C Chills/rigors Nausea/vomiting	☐ Pancytopenia] Marrow aplasia to extremities and		

	Ν	Н	S	Ν
NATIO				
SA	-EIY	NEI	WOR	K

	Hemolysis/Hemorrhage:	Disseminated intra	avascular coagula	ntion 🗌 Hemoglob	inemia	
-		Positive antibody	screen			
	Pain:	Abdominal pain	Back pain	🗌 Flank pain 📃	Infusion site pain	
-	Renal:	Hematuria	Hemoglobin			
	Respiratory:	Bronchospasm	Cough	Shortness	of breath	
	Other: (specify)					
	*Severity					
	Did the patient receive or	experience any of the	following?			
	□ No treatment required □ Symptomatic treatment only					
	Hospitalization, inlcuding prolonged hospitalization					
	☐ Disability and/or incapacitation ☐ Congenital anomaly or birth defect(s) of the fetus					
	Other medically important conditions					
	*Imputability					
	Which best describes the	relationship between t	he transfusion and	d the reaction?		
	No other alternative					
	Other potential causes are present (e.g., stem cell transplantation).					
	Alternative explanation	tions are more likely (e	.g., solid organ tra	ansplantation).		
	Evidence is clearly i	n favor of a cause othe	er than the transfu	sion, but transfusion ca	nnot be excluded.	
				cause other than the tra		
		2		fusion is unknown or no		
	Did the transfusion occur					
	WBC chimerism:] WBC chimerism pres	ent 🗌 WI	BC chimerism not prese	nt or not done	
Mc	odule-generated Desig	inations				
	TE: Designations for case		d imputability will	be automatically assigned	ed in the NHSN	
	plication based on response	-				
	*Do you agree with the	<u>case definition</u> desig	nation?	🗌 YES		
	^Please indicate your des					
	*Do you agree with the	severity designation?	?	☐ YES		
	^Please indicate your des					
	*Do you agree with the	imputability designat	ion?	YES		
	^Please indicate your des					
Pa	tient Treatment					
[Did the patient receive treat	tment for the transfusio	on reaction?	🗌 YES 🗌 NO		
	If yes, select treatment(s):					
	Medication (Select t	the type of medication)				
	Antipyretics	Antihistamines] Inotropes/Vasop	oressors 🗌 Bronchodi	lator 🗌 Diuretics	
	Intravenous In	nmunoglobulin 🗌 Inti	ravenous steroids	Corticosteroids	Antibiotics	
	Antithymocyte globulin Cyclosporin Other					
			-			
~		n (Intravenous colloids	- /			
υL	OC 57.316 Rev.2, v9.2	Page 3 o	014			



ATIONAL HEALTI							OMB No. Exp. Dat	n Approved 0920-0666 e: 01/31/25 lc.gov/nhsn
C Res	piratory support <i>(Sele</i>] Mechanical ventilation	· · ·	<i>pport)</i> wasive ventilation	🗌 Oxygen				
Renal replacement therapy (Select the type of therapy) Hemodialysis Peritoneal Continuous Veno-Venous Hemofiltration								
Phlebotomy Other Specify:								
Outcome								
Cause		·	on to death:	Minor or no sec			t determ	
	Details cular unit implicated	d in (i.e., respo	onsible for) the a	adverse	□ Ye	з П	No 「] N/A
reaction? Transfusion Start and End Date/Time	*Component code (check system used)	Amount transfused at reaction onset	[^] Unit number (Required for Infection and TRALI)	*Unit expiration Date/Time	*Bloc	od grou it	p	Implicat ed Unit?
^IMPLICATED			/					
1 1	□ ISBT-128							
,	Codabar	Entire unit			🗆 A-	🗆 A+	🗆 в-	
·		Partial unit mL			□в+	🗆 АВ-	🗆 AB+	Y
:				:	□ 0-	□ 0+	□ N/A	
:	🗌 Codabar	☐ Entire unit ☐ Partial unit			🗆 A-	□ A+	🗆 в-	N
1 1							🗆 AB+	IN
/		mL			□в+	🗆 AB-		
// :		mL		:	□ 0-	□ AB- □ O+	— □ N/A	
Custom Field		mL		:				
Custom Field		mL	Label	:				
	ds	mL	Label	:				
	ds	mL	Label	:				
Label	ds	mL	Label	:				